{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:10:24Z","timestamp":1791875424632,"version":"4.3.4"},"reference-count":133,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Epstein\u2013Barr (EBV) is a human \u03b3-herpesvirus that undergoes both a productive (lytic) cycle and a non-productive (latent) phase. The virus establishes enduring latent infection in B lymphocytes and productive infection in the oral mucosal epithelium. Like other herpesviruses, EBV expresses its genes in a coordinated pattern during acute infection. Unlike others, it replicates its DNA during latency to maintain the viral genome in an expanding pool of B lymphocytes, which are stimulated to divide upon infection. The reactivation from the latent state is associated with a productive gene expression pattern mediated by virus-encoded transcriptional activators BZLF-1 and BRLF-1. EBV is a highly transforming virus that contributes to the development of human lymphomas. Though viral vectors and mRNA platforms have been used to develop an EBV prophylactic vaccine, currently, there are no vaccines or antiviral drugs for the prophylaxis or treatment of EBV infection and EBV-associated cancers. Natural products and bioactive compounds are widely studied for their antiviral potential and capability to modulate intracellular signaling pathways. This review was intended to collect information on plant-derived products showing their antiviral activity against EBV and evaluate their feasibility as an alternative or adjuvant therapy against EBV infections and correlated oncogenesis in humans.<\/jats:p>","DOI":"10.3390\/v16010124","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:03:30Z","timestamp":1705377810000},"page":"124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Update of Natural Products and Their Derivatives Targeting Epstein\u2013Barr Infection"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-6057","authenticated-orcid":false,"given":"Rosamaria","family":"Pennisi","sequence":"first","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Trischitta","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"},{"name":"Department of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto 8, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"},{"name":"Department of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto 8, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-1724","authenticated-orcid":false,"given":"Assunta","family":"Venuti","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer (IARC), World Health Organization, 69366 Lyon, CEDEX 07, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Tamburello","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-7724","authenticated-orcid":false,"given":"Maria Teresa","family":"Sciortino","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr Virus Infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Rickinson","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein\u2013Barr Virus and Multiple Sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1572-5995(00)80051-4","article-title":"Natural Products as Antiviral Agents","volume":"24","year":"2000","journal-title":"Stud. Nat. Prod. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Musarra-Pizzo, M., Pennisi, R., Ben-Amor, I., Mandalari, G., and Sciortino, M.T. (2021). Antiviral Activity Exerted by Natural Products against Human Viruses. Viruses, 13.","DOI":"10.3390\/v13050828"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural Products in Drug Discovery: Advances and Opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Price, A.M., and Luftig, M.A. (2015). To Be or Not IIb: A Multi-Step Process for Epstein-Barr Virus Latency Establishment and Consequences for B Cell Tumorigenesis. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004656"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00430-018-0570-1","article-title":"Molecular Mechanisms of EBV-Driven Cell Cycle Progression and Oncogenesis","volume":"208","author":"Yin","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1059133","DOI":"10.3389\/fimmu.2022.1059133","article-title":"EBV-Associated Diseases: Current Therapeutics and Emerging Technologies","volume":"13","author":"Chakravorty","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/2326-6066.CIR-14-0203-T","article-title":"Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus\u2013Specific T-Cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma","volume":"3","author":"Zheng","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-Cells That Target Acute B-Lineage Leukemia Irrespective of CD19 Expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-981-10-7230-7_22","article-title":"Vaccine Development for Epstein-Barr Virus","volume":"1045","author":"Cohen","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13284","DOI":"10.1074\/jbc.M116.751644","article-title":"Bromodomain and Extraterminal Inhibitors Block the Epstein-Barr Virus Lytic Cycle at Two Distinct Steps","volume":"292","author":"Keck","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41419-018-0789-1","article-title":"BET Bromodomain Inhibitor JQ1 Preferentially Suppresses EBV-Positive Nasopharyngeal Carcinoma Cells Partially through Repressing c-Myc","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejps.2011.02.004","article-title":"Cimetidine: An Anticancer Drug?","volume":"42","author":"Kubecova","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014Cimetidine as an Anti-Cancer Agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120S","DOI":"10.1002\/j.1875-9114.1987.tb03536.x","article-title":"Immunologic Effects of Cimetidine: Potential Uses","volume":"7","author":"Mavligit","year":"1987","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632029800900309","article-title":"Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein\u2014Barr Virus Replication","volume":"9","author":"Meerbach","year":"1998","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0304-3835(00)00650-9","article-title":"Potential Use of Antiviral l(\u2212)Nucleoside Analogues for the Prevention or Treatment of Viral Associated Cancers","volume":"162","author":"Cheng","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/bs.aivir.2019.05.006","article-title":"Gammaherpesvirus Entry and Fusion: A Tale How Two Human Pathogenic Viruses Enter Their Host Cells","volume":"104","author":"Chen","year":"2019","journal-title":"Adv. Virus Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.20161846","article-title":"Human Immunity against EBV\u2014Lessons from the Clinic","volume":"214","author":"Tangye","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","article-title":"Human Complement Receptor Type 1\/CD35 Is an Epstein-Barr Virus Receptor","volume":"3","author":"Ogembo","year":"2013","journal-title":"Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein-Barr Virus Gp350\/220 Binding to the B Lymphocyte C3d Receptor Mediates Adsorption, Capping, and Endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.imlet.2021.06.006","article-title":"New Aspects in the Regulation of Human B Cell Functions by Complement Receptors CR1, CR2, CR3 and CR4","volume":"237","author":"Erdei","year":"2021","journal-title":"Immunol. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1128\/jvi.71.6.4657-4662.1997","article-title":"Epstein-Barr Virus Uses HLA Class II as a Cofactor for Infection of B Lymphocytes","volume":"71","author":"Li","year":"1997","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/JVI.74.5.2451-2454.2000","article-title":"Epstein-Barr Virus Entry Utilizing HLA-DP or HLA-DQ as a Coreceptor","volume":"74","author":"Haan","year":"2000","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","article-title":"GH\/GL Supercomplexes at Early Stages of Herpesvirus Entry","volume":"18","author":"Heldwein","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.str.2008.12.010","article-title":"Structure of Epstein-Barr Virus Glycoprotein 42 Suggests a Mechanism for Triggering Receptor-Activated Virus Entry","volume":"17","author":"Kirschner","year":"2009","journal-title":"Structure"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1073\/pnas.0810530106","article-title":"Structure of a Trimeric Variant of the Epstein\u2013Barr Virus Glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/JVI.74.14.6324-6332.2000","article-title":"Epstein-Barr Virus GH Is Essential for Penetration of B Cells but Also Plays a Role in Attachment of Virus to Epithelial Cells","volume":"74","author":"Molesworth","year":"2000","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.virol.2006.09.047","article-title":"Characterization of the Epstein\u2013Barr Virus Glycoprotein BMRF-2","volume":"359","author":"Xiao","year":"2007","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/s41467-020-19259-x","article-title":"Structure of Epstein-Barr Virus Tegument Protein Complex BBRF2-BSRF1 Reveals Its Potential Role in Viral Envelopment","volume":"11","author":"He","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16286","DOI":"10.1073\/pnas.0407320101","article-title":"Proteins of Purified Epstein-Barr Virus","volume":"101","author":"Johannsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2112457118","DOI":"10.1073\/pnas.2112457118","article-title":"A Widespread Viral Entry Mechanism: The C-End Rule Motif\u2013Neuropilin Receptor Interaction","volume":"118","author":"Balistreri","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin Receptor A2 Is a Functional Entry Receptor for Epstein\u2013Barr Virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","article-title":"Ephrin Receptor A2 Is an Epithelial Cell Receptor for Epstein\u2013Barr Virus Entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41467-020-19617-9","article-title":"Molecular Basis of EphA2 Recognition by GHgL from Gammaherpesviruses","volume":"11","author":"Su","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and Lytic Replication in Epstein\u2013Barr Virus-Associated Oncogenesis","volume":"17","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1128\/JVI.74.10.4512-4522.2000","article-title":"The Minimal Replicator of Epstein-Barr Virus OriP","volume":"74","author":"Yates","year":"2000","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1073\/pnas.181347998","article-title":"Human DNA Replication Initiation Factors, ORC and MCM, Associate with OriP of Epstein\u2013Barr Virus","volume":"98","author":"Chaudhuri","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.virol.2004.05.026","article-title":"Protein and Sequence Requirements for the Recruitment of the Human Origin Recognition Complex to the Latent Cycle Origin of DNA Replication of Epstein\u2013Barr Virus OriP","volume":"326","author":"Julien","year":"2004","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/rmv.441","article-title":"Latent and Lytic Epstein-Barr Virus Replication Strategies","volume":"15","author":"Tsurumi","year":"2005","journal-title":"Rev. Med. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/rmv.1780","article-title":"Switching of EBV Cycles between Latent and Lytic States","volume":"24","author":"Murata","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0092-8674(88)90028-1","article-title":"Identification and Characterization of OriLyt, a Lytic Origin of DNA Replication of Epstein-Barr Virus","volume":"55","author":"Hammerschmidt","year":"1988","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/sj.onc.1206556","article-title":"Epstein\u2013Barr Virus and Oncogenesis: From Latent Genes to Tumours","volume":"22","author":"Young","year":"2003","journal-title":"Oncogene"},{"key":"ref_49","unstructured":"Soni, V., Cahir-McFarland, E., and Kieff, E. (2007). TNF Receptor Associated Factors (TRAFs), Springer."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.1038\/sj.onc.1207905","article-title":"Epstein\u2013Barr Virus (EBV) LMP2A Mediates B-Lymphocyte Survival through Constitutive Activation of the Ras\/PI3K\/Akt Pathway","volume":"23","author":"Portis","year":"2004","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2018.00265","article-title":"Epstein\u2013Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis","volume":"8","author":"Malki","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1128\/JVI.01001-07","article-title":"Unique Signaling Properties of CTAR1 in LMP1-Mediated Transformation","volume":"81","author":"Mainou","year":"2007","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1073\/pnas.1019599108","article-title":"Epstein-Barr Virus Nuclear Antigens 3C and 3A Maintain Lymphoblastoid Cell Growth by Repressing P16INK4A and P14ARF Expression","volume":"108","author":"Maruo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","first-page":"2541","article-title":"Epstein-Barr Virus Nuclear Antigen (EBNA)3C Is an Immortalizing Oncoprotein with Similar Properties to Adenovirus E1A and Papillomavirus E7","volume":"13","author":"Parker","year":"1996","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.virol.2009.03.027","article-title":"Epstein\u2013Barr Virus Nuclear Antigen 3C Targets P53 and Modulates Its Transcriptional and Apoptotic Activities","volume":"388","author":"Yi","year":"2009","journal-title":"Virology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Feederle, R., Linnstaedt, S.D., Bannert, H., Lips, H., Bencun, M., Cullen, B.R., and Delecluse, H.-J. (2011). A Viral MicroRNA Cluster Strongly Potentiates the Transforming Properties of a Human Herpesvirus. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001294"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1128\/JVI.05100-11","article-title":"The Members of an Epstein-Barr Virus MicroRNA Cluster Cooperate to Transform B Lymphocytes","volume":"85","author":"Feederle","year":"2011","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/nar\/gkv1330","article-title":"The Expression of a Viral MicroRNA Is Regulated by Clustering to Allow Optimal B Cell Transformation","volume":"44","author":"Haar","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Seto, E., Moosmann, A., Gr\u00f6mminger, S., Walz, N., Grundhoff, A., and Hammerschmidt, W. (2010). Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of Primary Human B Cells. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001063"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2011.12.007","article-title":"Role of EBER and BARF1 in Nasopharyngeal Carcinoma (NPC) Tumorigenesis","volume":"22","author":"Takada","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2011.12.001","article-title":"The Role of MiRNAs and EBV BARTs in NPC","volume":"22","author":"Marquitz","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00804-17","DOI":"10.1128\/JVI.00804-17","article-title":"Coordinate Regulation of TET2 and EBNA2 Controls the DNA Methylation State of Latent Epstein-Barr Virus","volume":"91","author":"Lu","year":"2017","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e01987-16","DOI":"10.1128\/JVI.01987-16","article-title":"Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency","volume":"91","author":"Wille","year":"2017","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-319-22834-1_2","article-title":"EBNA2 and Its Coactivator EBNA-LP","volume":"Volume 391","author":"Kempkes","year":"2015","journal-title":"Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Szymula, A., Palermo, R.D., Bayoumy, A., Groves, I.J., Ba abdullah, M., Holder, B., and White, R.E. (2018). Epstein-Barr Virus Nuclear Antigen EBNA-LP Is Essential for Transforming Na\u00efve B Cells, and Facilitates Recruitment of Transcription Factors to the Viral Genome. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006890"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Styles, C., Paschos, K., White, R., and Farrell, P. (2018). The Cooperative Functions of the EBNA3 Proteins Are Central to EBV Persistence and Latency. Pathogens, 7.","DOI":"10.3390\/pathogens7010031"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Styles, C.T., Bazot, Q., Parker, G.A., White, R.E., Paschos, K., and Allday, M.J. (2017). EBV Epigenetically Suppresses the B Cell-to-Plasma Cell Differentiation Pathway While Establishing Long-Term Latency. PLoS Biol., 15.","DOI":"10.1371\/journal.pbio.2001992"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI58092","article-title":"EBNA3B-Deficient EBV Promotes B Cell Lymphomagenesis in Humanized Mice and Is Found in Human Tumors","volume":"122","author":"White","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-pathol-012513-104656","article-title":"Gammaherpesviruses and Lymphoproliferative Disorders","volume":"9","author":"Cesarman","year":"2014","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2328","DOI":"10.1002\/rmv.2328","article-title":"EBV Associated T- and NK-cell Lymphoproliferative Diseases: A Comprehensive Overview of Clinical Manifestations and Novel Therapeutic Insights","volume":"32","author":"Shafiee","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein\u2013Barr Virus and the Origins of Associated Lymphomas","volume":"350","author":"Gross","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, Virologic, and Immunologic Factors Associated with Acquisition and Severity of Primary Epstein\u2013Barr Virus Infection in University Students","volume":"207","author":"Balfour","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"205873842110026","DOI":"10.1177\/20587384211002621","article-title":"A Review: Mechanism of Action of Antiviral Drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1128\/jvi.66.6.3409-3414.1992","article-title":"Epstein-Barr virus enters B cells and epithelial cells by different routes","volume":"66","author":"Miller","year":"1992","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.18632\/oncotarget.3687","article-title":"Quercetin-Induced Apoptosis Prevents EBV Infection","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0166-3542(03)00030-5","article-title":"Mechanism of Action of Glycyrrhizic Acid in Inhibition of Epstein-Barr Virus Replication in Vitro","volume":"59","author":"Lin","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/10286020.2012.723203","article-title":"Fructus Gardenia (Gardenia Jasminoides J. Ellis) Phytochemistry, Pharmacology of Cardiovascular, and Safety with the Perspective of New Drugs Development","volume":"15","author":"Liu","year":"2013","journal-title":"J. Asian Nat. Prod. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12275-015-4672-9","article-title":"Genipin as a Novel Chemical Activator of EBV Lytic Cycle","volume":"53","author":"Son","year":"2015","journal-title":"J. Microbiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1080\/07391102.2020.1871074","article-title":"In Silico Analysis of Antiviral Phytochemicals Efficacy against Epstein\u2013Barr Virus Glycoprotein H","volume":"40","author":"Jakhmola","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1128\/AAC.00825-07","article-title":"Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus","volume":"52","author":"Isaacs","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/hep.24803","article-title":"(\u2212)-Epigallocatechin-3-Gallate Is a New Inhibitor of Hepatitis C Virus Entry","volume":"55","author":"Calland","year":"2012","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.001","article-title":"The Green Tea Catechin, Epigallocatechin Gallate Inhibits Chikungunya Virus Infection","volume":"113","author":"Weber","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1038\/s41598-020-61700-0","article-title":"Ginkgolic Acid Inhibits Fusion of Enveloped Viruses","volume":"10","author":"Borenstein","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Murata, T., Sugimoto, A., Inagaki, T., Yanagi, Y., Watanabe, T., Sato, Y., and Kimura, H. (2021). Molecular Basis of Epstein\u2013Barr Virus Latency Establishment and Lytic Reactivation. Viruses, 13.","DOI":"10.3390\/v13122344"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rosemarie, Q., and Sugden, B. (2020). Epstein\u2013Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111824"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Tan, H., Gong, Y., Liu, Y., Long, J., Luo, Q., Faleti, O.D., and Lyu, X. (2023). Advancing Therapeutic Strategies for Epstein-Barr Virus-Associated Malignancies through Lytic Reactivation. Biomed. Pharmacother., 164.","DOI":"10.1016\/j.biopha.2023.114916"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ben-Amor, I., Gargouri, B., Attia, H., Tlili, K., Kallel, I., Musarra-Pizzo, M., Sciortino, M.T., and Pennisi, R. (2021). In Vitro Anti-Epstein Barr Virus Activity of Olea europaea L. Leaf Extracts. Plants, 10.","DOI":"10.3390\/plants10112445"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11010-008-9984-1","article-title":"Induction of Epstein-Barr Virus (EBV) Lytic Cycle in Vitro Causes Oxidative Stress in Lymphoblastoid B Cell Lines","volume":"324","author":"Gargouri","year":"2009","journal-title":"Mol. Cell Biochem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s12011-011-9135-5","article-title":"Reactive Oxygen Species Production and Antioxidant Enzyme Expression after Epstein\u2013Barr Virus Lytic Cycle Induction in Raji Cell Line","volume":"144","author":"Gargouri","year":"2011","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11010-008-9755-z","article-title":"Epstein-Barr Virus Induces an Oxidative Stress during the Early Stages of Infection in B Lymphocytes, Epithelial, and Lymphoblastoid Cell Lines","volume":"313","author":"Lassoued","year":"2008","journal-title":"Mol. Cell Biochem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1593\/neo.05625","article-title":"Epstein-Barr Virus Infection Alters Cellular Signal Cascades in Human Nasopharyngeal Epithelial Cells","volume":"8","author":"Tsao","year":"2006","journal-title":"Neoplasia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3835(00)00353-0","article-title":"EBV DNA Polymerase Inhibition of Tannins from Eugenia Uniflora","volume":"154","author":"Lee","year":"2000","journal-title":"Cancer Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0968-0896(01)00361-3","article-title":"Synthesis of Novel Polyphenols Consisted of Ferulic and Gallic Acids, and Their Inhibitory Effects on Phorbol Ester-Induced Epstein\u2013Barr Virus Activation and Superoxide Generation","volume":"10","author":"Nomura","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jep.2017.11.016","article-title":"Potential Cancer Chemopreventive and Anticancer Constituents from the Fruits of Ficus hispida L.f. (Moraceae)","volume":"214","author":"Zhang","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hassan, S.T.S., \u0160udomov\u00e1, M., Mazurakova, A., and Kubatka, P. (2022). Insights into Antiviral Properties and Molecular Mechanisms of Non-Flavonoid Polyphenols against Human Herpesviruses. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213891"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"112493","DOI":"10.1016\/j.jep.2019.112493","article-title":"Bioactive Constituents of Lindernia crustacea and Its Anti-EBV Effect via Rta Expression Inhibition in the Viral Lytic Cycle","volume":"250","author":"Tsai","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wu, C.-C., Fang, C.-Y., Cheng, Y.-J., Hsu, H.-Y., Chou, S.-P., Huang, S.-Y., Tsai, C.-H., and Chen, J.-Y. (2017). Inhibition of Epstein-Barr Virus Reactivation by the Flavonoid Apigenin. J. Biomed. Sci., 24.","DOI":"10.1186\/s12929-016-0313-9"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"\u0160udomov\u00e1, M., Berchov\u00e1-B\u00edmov\u00e1, K., Mazurakova, A., \u0160amec, D., Kubatka, P., and Hassan, S.T.S. (2022). Flavonoids Target Human Herpesviruses That Infect the Nervous System: Mechanisms of Action and Therapeutic Insights. Viruses, 14.","DOI":"10.3390\/v14030592"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Eladwy, R.A., Vu, H.T., Shah, R., Li, C.G., Chang, D., and Bhuyan, D.J. (2023). The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021716"},{"key":"ref_100","first-page":"763","article-title":"(\u2212)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes","volume":"28","author":"Li","year":"2021","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"V\u00e1gv\u00f6lgyi, M., Girst, G., K\u00fasz, N., \u00d6tv\u00f6s, S.B., F\u00fcl\u00f6p, F., Hohmann, J., Servais, J.-Y., Seguin-Devaux, C., Chang, F.-R., and Chen, M.S. (2019). Less Cytotoxic Protoflavones as Antiviral Agents: Protoapigenone 1\u2032-O-Isopropyl Ether Shows Improved Selectivity Against the Epstein\u2013Barr Virus Lytic Cycle. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201912.0049.v1"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1099\/vir.0.031609-0","article-title":"Inhibition of the Epstein\u2013Barr Virus Lytic Cycle by Protoapigenone","volume":"92","author":"Tung","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1021\/np500988m","article-title":"Neo-Clerodane Diterpenoids from Scutellaria Barbata with Activity against Epstein\u2013Barr Virus Lytic Replication","volume":"78","author":"Wu","year":"2015","journal-title":"J. Nat. Prod."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kemboi, D., Peter, X., Langat, M., and Tembu, J. (2020). A Review of the Ethnomedicinal Uses, Biological Activities, and Triterpenoids of Euphorbia Species. Molecules, 25.","DOI":"10.3390\/molecules25174019"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/np400757k","article-title":"Potential Antiviral Lignans from the Roots of Saururus Chinensis with Activity against Epstein\u2013Barr Virus Lytic Replication","volume":"77","author":"Cui","year":"2014","journal-title":"J. Nat. Prod."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1142\/S0192415X16500166","article-title":"Litsea Species as Potential Antiviral Plant Sources","volume":"44","author":"Guan","year":"2016","journal-title":"Am. J. Chin. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1074\/jbc.RA120.012645","article-title":"The MTOR Inhibitor Manassantin B Reveals a Crucial Role of MTORC2 Signaling in Epstein-Barr Virus Reactivation","volume":"295","author":"Wang","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1631\/jzus.B1000336","article-title":"Inhibitory Activities of Microalgal Extracts against Epstein-Barr Virus DNA Release from Lymphoblastoid Cells","volume":"12","author":"Kok","year":"2011","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.antiviral.2009.12.002","article-title":"Inhibition of the Epstein\u2013Barr Virus Lytic Cycle by Moronic Acid","volume":"85","author":"Chang","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4149\/av_2014_01_76","article-title":"The Effect of Astragalus Polysaccharide on the Epstein-Barr Virus Lytic Cycle","volume":"58","author":"GUO","year":"2014","journal-title":"Acta Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/18715206113139990096","article-title":"Chemoprevention of Skin Cancer: Effect of Lawsonia Inermis L. (Henna) Leaf Powder and Its Pigment Artifact, Lawsone in the Epstein- Barr Virus Early Antigen Activation Assay and in Two-Stage Mouse Skin Carcinogenesis Models","volume":"13","author":"Kapadia","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.3390\/molecules15107115","article-title":"Inhibitory Effects of Resveratrol on the Epstein-Barr Virus Lytic Cycle","volume":"15","author":"Yiu","year":"2010","journal-title":"Molecules"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2012.09.003","article-title":"Resveratrol Inhibits Epstein Barr Virus Lytic Cycle in Burkitt\u2019s Lymphoma Cells by Affecting Multiple Molecular Targets","volume":"96","author":"Arena","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Lee, H., Lee, S., Shin, Y., Cho, M., Kang, H., and Cho, H. (2016). Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma. Molecules, 21.","DOI":"10.3390\/molecules21101286"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1248\/bpb.31.2018","article-title":"Inhibition of the Epstein-Barr Virus Lytic Cycle by Andrographolide","volume":"31","author":"Lin","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/molecules19011258","article-title":"Inhibition of Epstein-Barr Virus Lytic Cycle by an Ethyl Acetate Subfraction Separated from Polygonum cuspidatum Root and Its Major Component, Emodin","volume":"19","author":"Yiu","year":"2014","journal-title":"Molecules"},{"key":"ref_117","first-page":"3","article-title":"Inhibitory Effects of Polygonum Cuspidatum on the Epstein-Barr Virus Lytic Cycle","volume":"19","author":"Yiu","year":"2011","journal-title":"J. Food Drug Anal."},{"key":"ref_118","first-page":"20","article-title":"Inhibition of the Ethanolic Extract from Polygonum Cuspidatum Root on the Functions of Epstein-Barr Virus Latent Membrane Protein 1","volume":"21","author":"Yiu","year":"2013","journal-title":"J. Food Drug Anal."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"866","DOI":"10.18632\/oncoscience.110","article-title":"Cordycepin Is a Novel Chemical Suppressor of Epstein-Barr Virus Replication","volume":"1","author":"Ryu","year":"2014","journal-title":"Oncoscience"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ramayanti, O., Brinkkemper, M., Verkuijlen, S., Ritmaleni, L., Go, M., and Middeldorp, J. (2018). Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas. Cancers, 10.","DOI":"10.3390\/cancers10040089"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Liu, L., Yang, J., Ji, W., and Wang, C. (2019). Curcumin Inhibits Proliferation of Epstein\u2013Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/8592921"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3892\/or.2017.5489","article-title":"Berberine Inhibits the Proliferation of Human Nasopharyngeal Carcinoma Cells via an Epstein-Barr Virus Nuclear Antigen 1-Dependent Mechanism","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3892\/ijo.2016.3502","article-title":"Berberine Induces Mitochondrial Apoptosis of EBV-Transformed B Cells through P53-Mediated Regulation of XAF1 and GADD45\u03b1","volume":"49","author":"Park","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Tsang, C.M., Cheung, Y.C., Lui, V.W.-Y., Yip, Y.L., Zhang, G., Lin, V.W., Cheung, K.C.-P., Feng, Y., and Tsao, S.W. (2013). Berberine Suppresses Tumorigenicity and Growth of Nasopharyngeal Carcinoma Cells by Inhibiting STAT3 Activation Induced by Tumor Associated Fibroblasts. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-619"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"103802","DOI":"10.1016\/j.jff.2020.103802","article-title":"Berberine and Ginsenoside Rg3 Act Synergistically via the MAPK\/ERK Pathway in Nasopharyngeal Carcinoma Cells","volume":"66","author":"Zhou","year":"2020","journal-title":"J. Funct. Foods"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-018-0865-5","article-title":"Triptolide Inhibits Epstein-Barr Nuclear Antigen 1 Expression by Increasing Sensitivity of Mitochondria Apoptosis of Nasopharyngeal Carcinoma Cells","volume":"37","author":"Zhou","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bbrc.2014.12.023","article-title":"Triptolide Inhibits Proliferation of Epstein\u2013Barr Virus-Positive B Lymphocytes by down-Regulating Expression of a Viral Protein LMP1","volume":"456","author":"Zhou","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Huh, S., Lee, S., Choi, S.J., Wu, Z., Cho, J.-H., Kim, L., Shin, Y.S., Kang, B.W., Kim, J.G., and Liu, K. (2019). Quercetin Synergistically Inhibit EBV-Associated Gastric Carcinoma with Ganoderma lucidum Extracts. Molecules, 24.","DOI":"10.3390\/molecules24213834"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.biopha.2018.03.114","article-title":"Baicalein Inhibits Growth of Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma by Repressing the Activity of EBNA1 Q-Promoter","volume":"102","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1084\/jem.20040191","article-title":"Endogenous Presentation of CD8+ T Cell Epitopes from Epstein-Barr Virus\u2013Encoded Nuclear Antigen 1","volume":"199","author":"Tellam","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2020.00367","article-title":"Role of Viral and Host MicroRNAs in Immune Regulation of Epstein-Barr Virus-Associated Diseases","volume":"11","author":"Iizasa","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Apcher, S., Daskalogianni, C., Manoury, B., and F\u00e5hraeus, R. (2010). Epstein Barr Virus-Encoded EBNA1 Interference with MHC Class I Antigen Presentation Reveals a Close Correlation between MRNA Translation Initiation and Antigen Presentation. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001151"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1073\/pnas.90.18.8479","article-title":"Epstein-Barr Virus-Coded BHRF1 Protein, a Viral Homologue of Bcl-2, Protects Human B Cells from Programmed Cell Death","volume":"90","author":"Henderson","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/1\/124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:30Z","timestamp":1760104050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/1\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["v16010124"],"URL":"https:\/\/doi.org\/10.3390\/v16010124","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}